Nanoparticle-Mediated Drug Delivery for Treatment of Ischemic Heart Disease

46Citations
Citations of this article
119Readers
Mendeley users who have this article in their library.

Abstract

The regenerative capacity of an adult cardiac tissue is insufficient to repair the massive loss of heart tissue, particularly cardiomyocytes (CMs), following ischemia or other catastrophic myocardial injuries. The delivery methods of therapeutics agents, such as small molecules, growth factors, exosomes, cells, and engineered tissues have significantly advanced in medical science. Furthermore, with the controlled release characteristics, nanoparticle (NP) systems carrying drugs are promising in enhancing the cardioprotective potential of drugs in patients with cardiac ischemic events. NPs can provide sustained exposure precisely to the infarcted heart via direct intramyocardial injection or intravenous injection with active targets. In this review, we present the recent advances and challenges of different types of NPs loaded with agents for the repair of myocardial infarcted heart tissue.

Cite

CITATION STYLE

APA

Fan, C., Joshi, J., Li, F., Xu, B., Khan, M., Yang, J., & Zhu, W. (2020, June 24). Nanoparticle-Mediated Drug Delivery for Treatment of Ischemic Heart Disease. Frontiers in Bioengineering and Biotechnology. Frontiers Media S.A. https://doi.org/10.3389/fbioe.2020.00687

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free